Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Other financing activities: 2009-2025

Historic Other financing activities for Cytokinetics (CYTK) over the last 4 years, with Sep 2025 value amounting to $720,000.

  • Cytokinetics' Other financing activities was N/A to $720,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $30.2 million, marking a year-over-year change of. This contributed to the annual value of $19.6 million for FY2024, which is 86.66% up from last year.
  • As of Q3 2025, Cytokinetics' Other financing activities stood at $720,000, which was up 40.08% from $514,000 recorded in Q2 2025.
  • In the past 5 years, Cytokinetics' Other financing activities ranged from a high of $18.4 million in Q1 2024 and a low of $514,000 during Q2 2025.
  • Over the past 3 years, Cytokinetics' median Other financing activities value was $5.6 million (recorded in 2023), while the average stood at $7.5 million.
  • Data for Cytokinetics' Other financing activities shows a peak YoY spiked of 115.82% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Cytokinetics' Other financing activities stood at $4.4 million in 2021, then skyrocketed by 115.82% to $9.6 million in 2022, then grew by 9.53% to $10.5 million in 2023, then soared by 75.42% to $18.4 million in 2024, then reached $720,000 in 2025.
  • Its Other financing activities stands at $720,000 for Q3 2025, versus $514,000 for Q2 2025 and $18.4 million for Q1 2024.